世界の遅発性ジスキネジア治療市場(2024年~2028年)

◆英語タイトル:Global Tardive Dyskinesia Treatment Market 2024-2028

Technavioが発行した調査報告書(IRTNTR76758-24)◆商品コード:IRTNTR76758-24
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年11月8日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

遅発性ジスキネジア治療の世界市場 2024-2028遅発性ジスキネジア治療市場は2023-2028年に6億3,245万米ドルで成長し、予測期間中のCAGRは4.73%で加速すると予測されます。当レポートでは、遅発性ジスキネジア治療市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析を掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供します。精神疾患患者の増加、抗精神病薬処方の増加、神経疾患治療に対する膨大なアンメットニーズが市場を牽引しています。

Technavio社の遅発性ジスキネジア治療市場は以下のようにセグメント分けされています:
エンドユーザー別
- 病院薬局
- 小売薬局
- オンライン薬局

製品別
- Austedoおよびlngrezza
- アマンタジン
- その他

地域別
- 北米
- 欧州
- アジア
- その他の地域(ROW)

本調査では、今後数年間における遅発性ジスキネジア治療市場の成長を促進する主な要因の1つとして、遅発性ジスキネジアの治療に関する認識を広めるためのイニシアチブを挙げています。また、遅発性ジスキネジアの治療に対する規制当局の承認が進み、製薬企業による研究資金が増加していることも、市場の大きな需要につながるでしょう。

本レポートでは、遅発性ジスキネジア治療市場について以下の領域をカバーしています:
- 遅発性ジスキネジア治療市場サイジング
- 遅発性ジスキネジア治療市場予測
- 遅発性ジスキネジア治療市場産業分析

堅牢なベンダー分析は、クライアントが市場での地位を向上するのに役立つように設計されており、これに沿って、本レポートでは、Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.などを分析しています。また、遅発性ジスキネジア治療市場分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

当出版社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場概況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 世界の遅発性ジスキネジア治療市場規模:エンドユーザー別分析
7 世界の遅発性ジスキネジア治療市場規模:製品別分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global tardive dyskinesia treatment market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global tardive dyskinesia treatment market 2018 – 2022 ($ million)
o 4.2 End-user Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – End-user Segment 2018 – 2022 ($ million)
o 4.3 Product Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Product Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by End-user
o 6.1 Market segments
o Exhibit 30: Chart on End-user – Market share 2023-2028 (%)
o Exhibit 31: Data Table on End-user – Market share 2023-2028 (%)
o 6.2 Comparison by End-user
o Exhibit 32: Chart on Comparison by End-user
o Exhibit 33: Data Table on Comparison by End-user
o 6.3 Hospital pharmacy – Market size and forecast 2023-2028
o Exhibit 34: Chart on Hospital pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Hospital pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Hospital pharmacy – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Hospital pharmacy – Year-over-year growth 2023-2028 (%)
o 6.4 Retail pharmacy – Market size and forecast 2023-2028
o Exhibit 38: Chart on Retail pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Retail pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Retail pharmacy – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Retail pharmacy – Year-over-year growth 2023-2028 (%)
o 6.5 Online pharmacy – Market size and forecast 2023-2028
o Exhibit 42: Chart on Online pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 43: Data Table on Online pharmacy – Market size and forecast 2023-2028 ($ million)
o Exhibit 44: Chart on Online pharmacy – Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Online pharmacy – Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by End-user
o Exhibit 46: Market opportunity by End-user ($ million)
o Exhibit 47: Data Table on Market opportunity by End-user ($ million)
• 7 Market Segmentation by Product
o 7.1 Market segments
o Exhibit 48: Chart on Product – Market share 2023-2028 (%)
o Exhibit 49: Data Table on Product – Market share 2023-2028 (%)
o 7.2 Comparison by Product
o Exhibit 50: Chart on Comparison by Product
o Exhibit 51: Data Table on Comparison by Product
o 7.3 Austedo and Ingrezza – Market size and forecast 2023-2028
o Exhibit 52: Chart on Austedo and Ingrezza – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Austedo and Ingrezza – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Austedo and Ingrezza – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Austedo and Ingrezza – Year-over-year growth 2023-2028 (%)
o 7.4 Amantadine and others – Market size and forecast 2023-2028
o Exhibit 56: Chart on Amantadine and others – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Amantadine and others – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Amantadine and others – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Amantadine and others – Year-over-year growth 2023-2028 (%)
o 7.5 Market opportunity by Product
o Exhibit 60: Market opportunity by Product ($ million)
o Exhibit 61: Data Table on Market opportunity by Product ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 67: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 83: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Germany – Market size and forecast 2023-2028
o Exhibit 87: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.9 UK – Market size and forecast 2023-2028
o Exhibit 91: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.10 China – Market size and forecast 2023-2028
o Exhibit 95: Chart on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.11 France – Market size and forecast 2023-2028
o Exhibit 99: Chart on France – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on France – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on France – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on France – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 111: Abbott Laboratories – Overview
o Exhibit 112: Abbott Laboratories – Business segments
o Exhibit 113: Abbott Laboratories – Key news
o Exhibit 114: Abbott Laboratories – Key offerings
o Exhibit 115: Abbott Laboratories – Segment focus
o 12.4 Alembic Pharmaceuticals Ltd.
o Exhibit 116: Alembic Pharmaceuticals Ltd. – Overview
o Exhibit 117: Alembic Pharmaceuticals Ltd. – Product / Service
o Exhibit 118: Alembic Pharmaceuticals Ltd. – Key offerings
o 12.5 Aspire Pharma Ltd.
o Exhibit 119: Aspire Pharma Ltd. – Overview
o Exhibit 120: Aspire Pharma Ltd. – Product / Service
o Exhibit 121: Aspire Pharma Ltd. – Key offerings
o 12.6 Centaur Pharmaceuticals Pvt. Ltd.
o Exhibit 122: Centaur Pharmaceuticals Pvt. Ltd. – Overview
o Exhibit 123: Centaur Pharmaceuticals Pvt. Ltd. – Product / Service
o Exhibit 124: Centaur Pharmaceuticals Pvt. Ltd. – Key offerings
o 12.7 Cipla Ltd.
o Exhibit 125: Cipla Ltd. – Overview
o Exhibit 126: Cipla Ltd. – Business segments
o Exhibit 127: Cipla Ltd. – Key news
o Exhibit 128: Cipla Ltd. – Key offerings
o Exhibit 129: Cipla Ltd. – Segment focus
o 12.8 Lannett Co. Inc.
o Exhibit 130: Lannett Co. Inc. – Overview
o Exhibit 131: Lannett Co. Inc. – Product / Service
o Exhibit 132: Lannett Co. Inc. – Key offerings
o 12.9 Luye Pharma Group Ltd.
o Exhibit 133: Luye Pharma Group Ltd. – Overview
o Exhibit 134: Luye Pharma Group Ltd. – Business segments
o Exhibit 135: Luye Pharma Group Ltd. – Key offerings
o Exhibit 136: Luye Pharma Group Ltd. – Segment focus
o 12.10 Neurocrine Biosciences Inc.
o Exhibit 137: Neurocrine Biosciences Inc. – Overview
o Exhibit 138: Neurocrine Biosciences Inc. – Product / Service
o Exhibit 139: Neurocrine Biosciences Inc. – Key offerings
o 12.11 Novartis AG
o Exhibit 140: Novartis AG – Overview
o Exhibit 141: Novartis AG – Business segments
o Exhibit 142: Novartis AG – Key offerings
o Exhibit 143: Novartis AG – Segment focus
o 12.12 Psicofarma S. A. de C. V
o Exhibit 144: Psicofarma S. A. de C. V – Overview
o Exhibit 145: Psicofarma S. A. de C. V – Product / Service
o Exhibit 146: Psicofarma S. A. de C. V – Key offerings
o 12.13 Sawai Group Holdings Co. Ltd.
o Exhibit 147: Sawai Group Holdings Co. Ltd. – Overview
o Exhibit 148: Sawai Group Holdings Co. Ltd. – Product / Service
o Exhibit 149: Sawai Group Holdings Co. Ltd. – Key offerings
o 12.14 SOM Innovation Biotech S.A.
o Exhibit 150: SOM Innovation Biotech S.A. – Overview
o Exhibit 151: SOM Innovation Biotech S.A. – Product / Service
o Exhibit 152: SOM Innovation Biotech S.A. – Key offerings
o 12.15 SteriMax Inc.
o Exhibit 153: SteriMax Inc. – Overview
o Exhibit 154: SteriMax Inc. – Product / Service
o Exhibit 155: SteriMax Inc. – Key offerings
o 12.16 Sun Pharmaceutical Industries Ltd.
o Exhibit 156: Sun Pharmaceutical Industries Ltd. – Overview
o Exhibit 157: Sun Pharmaceutical Industries Ltd. – Product / Service
o Exhibit 158: Sun Pharmaceutical Industries Ltd. – Key offerings
o 12.17 Teva Pharmaceutical Industries Ltd.
o Exhibit 159: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 160: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 161: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 162: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 163: Teva Pharmaceutical Industries Ltd. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 164: Inclusions checklist
o Exhibit 165: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 166: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 167: Research methodology
o Exhibit 168: Validation techniques employed for market sizing
o Exhibit 169: Information sources
o 13.5 List of abbreviations
o Exhibit 170: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by End-user
Exhibits6: Executive Summary – Chart on Market Segmentation by Product
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global tardive dyskinesia treatment market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – End-user Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Product Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on End-user – Market share 2023-2028 (%)
Exhibits31: Data Table on End-user – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by End-user
Exhibits33: Data Table on Comparison by End-user
Exhibits34: Chart on Hospital pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Hospital pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Hospital pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Hospital pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Retail pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Retail pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Retail pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Retail pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Online pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Online pharmacy – Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Online pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Online pharmacy – Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by End-user ($ million)
Exhibits47: Data Table on Market opportunity by End-user ($ million)
Exhibits48: Chart on Product – Market share 2023-2028 (%)
Exhibits49: Data Table on Product – Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Product
Exhibits51: Data Table on Comparison by Product
Exhibits52: Chart on Austedo and Ingrezza – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Austedo and Ingrezza – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Austedo and Ingrezza – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Austedo and Ingrezza – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Amantadine and others – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Amantadine and others – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Amantadine and others – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Amantadine and others – Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Product ($ million)
Exhibits61: Data Table on Market opportunity by Product ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on China – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on China – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on France – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on France – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on France – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on France – Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Abbott Laboratories – Overview
Exhibits112: Abbott Laboratories – Business segments
Exhibits113: Abbott Laboratories – Key news
Exhibits114: Abbott Laboratories – Key offerings
Exhibits115: Abbott Laboratories – Segment focus
Exhibits116: Alembic Pharmaceuticals Ltd. – Overview
Exhibits117: Alembic Pharmaceuticals Ltd. – Product / Service
Exhibits118: Alembic Pharmaceuticals Ltd. – Key offerings
Exhibits119: Aspire Pharma Ltd. – Overview
Exhibits120: Aspire Pharma Ltd. – Product / Service
Exhibits121: Aspire Pharma Ltd. – Key offerings
Exhibits122: Centaur Pharmaceuticals Pvt. Ltd. – Overview
Exhibits123: Centaur Pharmaceuticals Pvt. Ltd. – Product / Service
Exhibits124: Centaur Pharmaceuticals Pvt. Ltd. – Key offerings
Exhibits125: Cipla Ltd. – Overview
Exhibits126: Cipla Ltd. – Business segments
Exhibits127: Cipla Ltd. – Key news
Exhibits128: Cipla Ltd. – Key offerings
Exhibits129: Cipla Ltd. – Segment focus
Exhibits130: Lannett Co. Inc. – Overview
Exhibits131: Lannett Co. Inc. – Product / Service
Exhibits132: Lannett Co. Inc. – Key offerings
Exhibits133: Luye Pharma Group Ltd. – Overview
Exhibits134: Luye Pharma Group Ltd. – Business segments
Exhibits135: Luye Pharma Group Ltd. – Key offerings
Exhibits136: Luye Pharma Group Ltd. – Segment focus
Exhibits137: Neurocrine Biosciences Inc. – Overview
Exhibits138: Neurocrine Biosciences Inc. – Product / Service
Exhibits139: Neurocrine Biosciences Inc. – Key offerings
Exhibits140: Novartis AG – Overview
Exhibits141: Novartis AG – Business segments
Exhibits142: Novartis AG – Key offerings
Exhibits143: Novartis AG – Segment focus
Exhibits144: Psicofarma S. A. de C. V – Overview
Exhibits145: Psicofarma S. A. de C. V – Product / Service
Exhibits146: Psicofarma S. A. de C. V – Key offerings
Exhibits147: Sawai Group Holdings Co. Ltd. – Overview
Exhibits148: Sawai Group Holdings Co. Ltd. – Product / Service
Exhibits149: Sawai Group Holdings Co. Ltd. – Key offerings
Exhibits150: SOM Innovation Biotech S.A. – Overview
Exhibits151: SOM Innovation Biotech S.A. – Product / Service
Exhibits152: SOM Innovation Biotech S.A. – Key offerings
Exhibits153: SteriMax Inc. – Overview
Exhibits154: SteriMax Inc. – Product / Service
Exhibits155: SteriMax Inc. – Key offerings
Exhibits156: Sun Pharmaceutical Industries Ltd. – Overview
Exhibits157: Sun Pharmaceutical Industries Ltd. – Product / Service
Exhibits158: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibits159: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits160: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits161: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits162: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits163: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits164: Inclusions checklist
Exhibits165: Exclusions checklist
Exhibits166: Currency conversion rates for US$
Exhibits167: Research methodology
Exhibits168: Validation techniques employed for market sizing
Exhibits169: Information sources
Exhibits170: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の遅発性ジスキネジア治療市場(2024年~2028年)(Global Tardive Dyskinesia Treatment Market 2024-2028)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆